Organized by:

Under the auspices:

Melanoma Bridge

Naples, Royal Continental Hotel
December 2nd - 4th, 2012

BACKGROUND

Melanoma Bridge Naples, December 2nd - 4th 2012

In the last years, when advancement in understanding the molecular basis of melanoma has made possible the identification of molecular targets and of active specific immunization with important implications in clinical practice, landmark progress has been made in the treatment of cancer and, melanoma in particular. Since then, new therapeutic approaches have been emerging from basic science and translating into clinical practice by active clinical investigation. To disclose and stimulate the discussion of new approaches and strategies in the field of melanoma, more than 40 international faculty members will join "Melanoma Brigde meeting". After the first meeting "Melanoma Research: a bridge Naples-USA" (Naples, Dec 6-7th 2010) and the second edition "Melanoma Research: a bridge from Naples to the World" (Naples, Dec 5-6th 2011), "Melanoma Bridge 2012" will take place from December 2nd to 4th 2012 in Naples, jointly organized by Istituto Nazionale Tumori Fondazione "G. Pascale" and Fondazione Melanoma Onlus, together with the Society for ImmunoTherapy of Cancer (SITC) and the National Institute of Health (NIH) Presidents of the event are Paolo A. Ascierto (INT, Naples, Italy), Francesco M. Marincola (NIH, Bethesda, USA), and Nicola Mozzillo (INT, Naples, Italy) and, together with the Scientific Board, including well-known experts covering different areas and based in different Countries, aim at achieving a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and the biology of the cancer microenvironment.
Attendees are expected from Italy and from all around the world. In addition, for the first time, representatives of melanoma patient associations are invited to join the event.

SCIENTIFIC PROGRAM CME EVENT

DECEMBER 2nd

17:00 Opening Ceremony
Chair: ***Nicola Mozzillo, Franco Marincola***

17.10 La storia del melanoma in Italia raccontata da Pino Cascinelli
Natale Cascinelli

17.30 State of the Art in target therapy for melanoma
Paolo A. Ascierto

17.50 L'esperienza dei pazienti
Francesco Brancaccio, *Responsabile Area Pazienti Fondazione Melanoma Onlus*

18.00 Melanoma & Research
Valerie Guild, *President of the AIM at Melanoma Foundation*

18.10 *Tavola Rotonda: Esperti e pazienti*
Moderatore: ***Carlo Gargiulo****
Michele Maio*, Presidente Eletto NIBIT, Network Italiano per la Bioterapia dei Tumori*
Carmine Pinto*, Segretario Nazionale AIOM, Associazione Italiana di Oncologia Medica*
Carlo Riccardo Rossi*, Presidente IMI, Intergruppo Melanoma Italiano*

SCIENTIFIC PROGRAM CME EVENT

Francesco De Lorenzo*, Presidente FAVO*
Giuseppe Palmieri*, Presidente Humana Onlus*
Luigi De Magistris*, Sindaco di Napoli*
Stefano Caldoro*, Presidente Regione Campania*

19.30 Award Ceremony
The Melanoma Foundation Honorary Lecture on Melanoma Research and Treatment

20.00 *Welcome Cocktail*

20.30 *Congress Official Dinner*

** invited to participate*

SCIENTIFIC PROGRAM CME EVENT

DECEMBER 3rd

MOLECULAR ADVANCES AND BIOMARKERS

Chairmen: ***Magdalena Thurin, Franco Marincola***

9:30 Mage-A3 Antigen Specific Immunotherapy: spontaneous and induced immune response
Vincent Brichard

10:00 Cancer/antigen expression and correlations with immune responses and clinical events
Sacha Gnjatic

10:30 The melanoma tumor microenvironment: biomarkers to biology
Thomas F. Gajewski

11:00 Biomarkers predicting response to immunotherapy
Helen Gogas

11:30 *Break*

11:45 Single Cell Network Profiling (SCNP): technology and its application to the development of cancer immunotherapy
Alessandra Cesano

SCIENTIFIC PROGRAM CME EVENT

12:15 New Markers of Melanoma Metastasis
Mohamed Kashani Sabet

12:45 How melanoma escapes from MAPK inhibition
Roger Lo

13:15 *Lunch*

COMBINATION THERAPIES
Chairmen: ***Paolo A. Ascierto, Nicola Mozzillo***

14:50 Current and Future Options for Adjuvant Therapy of Melanoma
John Kirkwood

15:20 Combinatorial Immunotherapeutic strategies
Soldano Ferrone

15:50 BRAFV600E targeted therapy and adoptive cell transfer immunotherapy
Nicolas Acquavella

16:20 Oncolytic Viral Therapy for the Treatment of Melanoma
Howard Kaufman

16:50 *Break*

SCIENTIFIC PROGRAM CME EVENT

17:00 Drug development in the era of molecular medicine: lessons from BRAF inhibitors in melanoma
Igor Puzanov

17:30 Effects of paradoxical activation of the MAPK pathway with BRAF inhibitors
Antoni Ribas

18:00 Strategies to overcome BRAF inhibitor resistance with combination therapy
Jeff Sosman

18:30 Novel Molecular Targets in Melanoma
Grant McArthur

19:00 Closing remarks

SCIENTIFIC PROGRAM CME EVENT

DECEMBER 4th

NOVEL CONCEPT
Chairmen: ***Paola Queirolo, Nicola Normanno***

9:20 Fondazione Melanoma award lecture: Inflammation and the commensal flora affect the tumor microenvironment and the response to therapy
Giorgio Trinchieri

9:50 Immuno-stromal modulation: the balance can tip either way
Lex Eggermont

10:20 Intratumour Heterogeneity: is it relevant?
James Larkin

10:50 Brain metastases in the era of molecularly targeted and immunomodulatory therapies
Kim Margolin

11:20 Phase III, Randomized, Open-Label, Multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM)
Michele Del Vecchio

SCIENTIFIC PROGRAM CME EVENT

11:30 *Break*

11:45 The complexity of tumor biology challenge immune responsiveness
Ena Wang

12:00 Diversity and avidity: frequently neglected, yet key parameters of the anti-tumor T cell response
Paul V. Lehmann

12:15 Evaluation of therapeutic strategies in a genetically engineered mouse model for melanoma
Rienk Offringa

12:45 Technological development, research and melanoma treatment: introperative 3D-Spect, dendritic cells and elettrochemotherapy
Lorenzo Borgognoni

13:10 Chemosaturation Therapy: Creating New Options in the Management of Patients with Liver Dominant Disease
Mark Faries

13:30 *Lunch*

SCIENTIFIC PROGRAM CME EVENT

BRIDGE BETWEEN MELANOMA AND COLO-RECTAL CANCER: BIOLOGY OF TUMOR MICROENVIRONMENT

Chairmen: ***Fernando Vidal-Vanaclocha, Gennaro Ciliberto***

14:30 Selective biomarkers and immune modulatory molecules as targets for (immune) therapies of melanoma
Barbara Seliger

15:00 Effects of pH regulation on melanoma immunity
Licia Rivoltini

15:30 Cancer related Inflammation in tumor progression
Alberto Mantovani

16:00 Vaccine strategy targeting antigens expressed by tumors in their microenvironment
Bernard A. Fox

16:30 *Break*

16:45 Optimization of synthetic therapeutic vaccines for viral and non-viral cancer
Cornelis Melief

SCIENTIFIC PROGRAM CME EVENT

17:15 The MESOT-TREM Study: anti-CTLA-4 treatment of chemotherapy-resistant mesothelioma patients.
Luana Calabrò

17:45 The hepatic metastasis microenvironment for melanoma and colon cancer cells
Fernando Vidal-Vanaclocha

18:15 A new approach for the classification of cancer in the era of immunotherapy
Jérôme Galon

18:45 Closing remarks

19:15 CME Test

PRESIDENTS and SCIENTIFIC BOARD

PRESIDENTS:

Paolo A. Ascierto
Vice Director of the Unit of Medical Oncology and Innovative Therapies, Istituto Tumori Fondazione Pascale, Naples, Italy

Francesco M. Marincola
Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health in Bethesda, Maryland

Nicola Mozzillo
Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

SCIENTIFIC BOARD:

Paolo A. Ascierto
Vice Director of the Unit of Medical Oncology and Innovative Therapies, Istituto Tumori Fondazione Pascale, Naples, Italy

Gennaro Ciliberto
Scientific Director of the National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Bernard A. Fox
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

PRESIDENTS and SCIENTIFIC BOARD

Jérôme Galon
Research Director at INSERM (National Institute of Health and Medical Research), Paris, France

John M. Kirkwood
Professor of Clinical and Translational Science, Clinical and Translational Science Institute, University of Pittsburgh, Pennsylvania

Francesco M. Marincola
Chief of the Infectious Disease and Immunogenetics Section in the Department of Transfusion Medicine at the Clinical Center of the National Institutes of Health in Bethesda, Maryland

Nicola Mozzillo
Director of the Department Melanoma and Soft Tissues, Istituto Tumori - Fondazione G. Pascale, Naples, Italy

Antoni Ribas
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, California

Giorgio Trinchieri
Director of the Cancer and Inflammation Program and Chief of the Laboratory of Experimental Immunology, NCI, NIH, Maryland

PRESIDENTS and SCIENTIFIC BOARD

Fernando Vidal-Vanaclocha
Professor of Cell Biology and Human Histology, Vice Dean for Research and International Affairs and Scientific Director of the Institute of Applied Molecular Medicine (IMMA) at the CEU-San Pablo University School of Medicine, Madrid, Spain

Ena Wang
Director of Molecular Science, Infectious Diseases and Immunogenetics Section, Department of Transfusion Medicine, CC, NIH, Maryland

SPEAKERS and MODERATORS

Nicolas Acquavella
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Lorenzo Borgognoni
Plastic Surgery Unit, Regional Melanoma Referral Center, SM Annunziata Hospital, Tuscan Tumor Institute, Florence, Italy

Vincent Brichard
Vice President & Head of Immunotherapeutics at GlaxoSmithKline Biologicals, Belgium

Luana Calabrò
Medical Oncology and Immunotherapy, University Hospital, Siena, Italy

Alessandra Cesano
Clinical Affairs, Nodality Inc., South San Francisco, California

Michele Del Vecchio
Unit of Medical Oncology 1, Department of Medical Oncology, Fondazione IRCCS stituto Nazionale Tumori, Milan, Italy

Lex Eggermont
Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

SPEAKERS and MODERATORS

Mark Faries
Department of Surgical Oncology, John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, California

Soldano Ferrone
Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts

Thomas F. Gajewski
Department of Pathology and Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois

Sacha Gnjatic
Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York City, New York

Helen Gogas
1st Department of Medicine, "Laiko" General Hospital, University of Athens, Greece

Mohamed Kashani-Sabet
Center for Melanoma Research and Treatment, California Pacific Medical Center and CPMC Research Institute, San Francisco, California

SPEAKERS and MODERATORS

Howard Kaufman
The Tumor Immunology Laboratory & Department of General Surgery, Rush University Medical Center, Chicago, Illinois

James Larkin
Department of Medicine, The Royal Marsden Hospital, London, UK

Paul V. Lehmann
CEO of Cellular Technology Ltd and Adjunct Professor at CWRU, Cleveland, Ohio

Roger Lo
Assistant Professor of Medicine/Dermatology & Molecular and Medical Pharmacology Director, Melanoma Clinic in Dermatology. Member, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA

Alberto Mantovani
Istituto Clinico Humanitas IRCCS and Dept. Translational Medicine, University of Milan, Italy

Kim Margolin
Medical Oncology, University of Washington, Seattle, Washington

Grant McArthur
Divisions of Cancer Medicine and Cancer Research, Peter MacCallum Cancer Centre, Victoria, Australia

SPEAKERS and MODERATORS

Cornelis Melief
Leiden University Medical center, Leiden, The Netherlands

Igor Puzanov
Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

Nicola Normanno
Cell Biology and Biotherapy Unit, INT Fondazione G. Pascale, Naples, Italy

Rienk Offringa
Head Div. Molecular Oncology of Gastrointestinal Cancers, German Cancer Research Center, Heidelberg, Germany

Paola Queirolo
San Martino Hospital, National Institute for Cancer Research, Genoa, Italy

Licia Rivoltini
Unit of Immunotherapy of Human Tumours, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Barbara Seliger
Institute of Medical Immunology, Martin-Luther-University Halle-Wittenberg, Saale, Germany

SPEAKERS and MODERATORS

Jeff Sosman
Division of Hematology/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

Magdalena Thurin
Cancer Diagnosis Program, NCI, NIH, Rockville, Maryland

GENERAL INFORMATION

CME PROVIDER AND ORGANISING AGENCY:

3P Solution Srl
Via Carducci 12, 20123 Milan
Phone +39 02 36631574 - +39 349 6485434
Fax +39 02 89098927
www.3psolution.it
info@3psolution.it

CONGRESS VENUE:

Royal Continental Hotel
Via Partenope, 38-44
80121 - Naples
Phone +39 081 245 2068
www.royalgroup.it/royalcontinental/

OFFICIAL LANGUAGE:

The official language is English

GENERAL INFORMATION

REGISTRATION:

Only registered attendees will be admitted to the meeting.

The registration fee includes:

- participation in the scientific program
- CME credits
- coffee breaks and lunches for December, 3rd, 4th.
- congress bag

Participants are kindly requested to inform us about any dietary habit (i.e. food allergies/ intolerances, vegetarian or vegan habits).

OFFICIAL CONGRESS DINNER:

Official Congress dinner will be held on December 2nd.

It will be possible to register for the Congress dinner (€ 125,00) by contacting us at *info@melanomabridge.org* or at the registration desk before December 2nd at 2 p.m.

GENERAL INFORMATION



3PS
3PSolution

GENERAL INFORMATION

BRIDGE MEETING ATTENDANCE

CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Provider (code 327) and has a quality-management system that meets the requirements of UNI EN ISO 9001:2008, with CSQA certificate no. 23887.

Melanoma Bridge is accredited by the Italian Ministry of Health for 16 CME credits.
The specialties and disciplines eligible for CME credits are: Medical Doctors, Pharmacists, Biologists, and Nurses.
This event has been accredited for 100 participants.

In order to receive credits, participants must:

1. Attend all the accredited sessions;
2. Complete the assessment test at the end of the congress (a grade of 75% must be obtained to receive CME credit);
3. Complete the evaluation questions at the end of the congress.

CME certificate attendance will be sent to the participants at the end of the evaluation procedure.
The educational material related to the event will be available to participants on the website *www.3psolution.it* upon registration.

ORGANIZED BY

Fondazione Melanoma Onlus

Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale"

National Institutes of Health

Society for Immunotherapy of Cancer

UNDER THE AUSPICES

Associazione Italiana di Oncologia Medica

European Society for Medical Oncology

Regione Campania

Comune di Napoli

This CME event has been sponsored by an *unrestricted grant* from:

GOLD SPONSOR

Bristol-Myers Squibb

SILVER SPONSOR

Celgene
Committed to improving the lives of patients worldwide®

CEA
CLINICAL BIOPHYSICS

Roche

SPONSOR

C.T.L. Europe GmbH

Delcath Systems, Inc.
Concentrating the Power of Chemotherapy

ITALFARMACO
ONCOLOGIA

VENTANA
A Member of the Roche Group